查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1918125

多重检测市场－2026-2031年预测

Multiplex Assay Market - Forecast from 2026 to 2031
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 150 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

多重检测市场预计将从 2025 年的 1,607,267,000 美元成长到 2031 年的 3,806,265,000 美元，复合年增长率为 15.45%。

多重检测市场正经历显着成长，这主要得益于技术进步、医疗保健模式的转变以及对分析复杂性日益增长的需求。这些先进的科学技术能够同时测量单一样本中的多种分析物或标靶，已成为生物化学、分子生物学、医学和诊断领域不可或缺的工具。生物技术产业的扩张、个人化医疗的引入以及慢性病盛行率的上升，都为市场发展注入了强劲动力。

主要市场驱动因素

固有的技术优势

多重检测相比传统的单重检测具有显着优势，使其在科学研究、诊断和临床应用中极具价值。其最显着的优势在于能够同时分析单一样本中的多种分析物，包括蛋白质、核酸和其他分子。这种能力能够提供对生物过程、疾病路径和药物反应的全面而整体的洞察，而这是传统的单重检测无法实现或难以实现的。

此外，多重检测透过同时检测多种生物标记和疾病指标，提高了诊断准确性。这种多变量方法降低了假阳性和假阴性的机率，从而可能获得更可靠的结果并改善患者预后。同时分析多个标靶的效率提升，意味着所需检体量减少、试剂消耗降低、结果报告速度加快以及每个资料点的总体成本降低——所有这些因素在研究和临床应用中都至关重要。

製药和生物技术领域的扩张

不断扩张的製药业和分子诊断技术的进步是推动市场发展的催化剂。生物技术、基因组学和蛋白​​质组学的持续发展使得许多潜在生物标记和治疗标靶得以被发现。多重检测在同时评估药物对多个标靶的潜在作用方面发挥关键作用，从而加快药物研发进程并提高研究效率。生物技术产业正在快速发展，预计到2025年，印度生物技术Start-Ups将达到1万家，这表明该行业在全球范围内呈现增长态势，并体现了对多重检测等先进分析工具日益增长的需求。

融入个人化医疗

医疗产业向个人化医疗转型需要对多种生物标记有全面的​​了解，这使得多重检测成为一项至关重要的基础技术。这些检测能够同时分析多种遗传、蛋白质组和分子标记物，从而支持开发针对个别患者优化的个人化治疗策略。新型经营模式的出现推动了个人化医疗的广泛应用。例如，总部位于纽约的Start-UpsMalla 于 2023 年 5 月推出了其服务。该公司透过每月 65 美元的会员制模式提供功能性和个人化医疗服务，其中包括一对一的个人化健康计画咨询。

慢性病和人口压力

多重检测技术已被证明在慢性病研究和管理中极为有用，它能够追踪生物标记随时间的变化，并深入了解疾病动态。慢性病盛行率的不断上升是一个重要的成长要素，这些疾病每年导致4,100万人死亡（占全球所有死亡人数的74%）。多重检测技术的分析能力使得全面监测和管理策略成为可能，而这些策略使用传统方法则难以实现。

此外，人口老化也推动了多重检测的需求，因为老年人通常患有多种合併症，例如心血管疾病和糖尿病，这些疾病需要复杂的诊断方法。人口结构变化显着，预计2015年至2050年间，全球60岁及以上人口的比例将从12%增至22%，这将持续推动对高效多分析物诊断解决方案的需求。

市场限制

儘管多重检测市场成长前景强劲，但仍面临一些可能影响其扩张的挑战。成本是限制阻碍因素之一，多重检测的初始成本和持续成本仍然相对较高。这些成本包括仪器购买、试剂以及检测设计和数据分析所需的专业知识。这些财务障碍可能会限制其应用，尤其是在资源受限的环境中，预算限制使得投资先进的分析平台变得困难。

此外，设计和优化多重检测比传统的单重检测方法更复杂，因为必须仔细考虑交叉反应性、灵敏度和每个分析物的动态范围等因素，这使得开发过程更加耗时且耗力。

区域和近期趋势

预计在预测期内，北美将占据显着的市场份额，这主要得益于慢性病的高发生率、老年人口的增长、药物研发投入的增加以及政府的支持。截至2020年，美国约有六分之一的人口年龄在65岁及以上，这推动了多重检测的需求。

近期市场趋势凸显了持续创新的重要性。 2023年2月，Quansys Biosciences推出了一条用于非人灵长类动物模型的多重ELISA检验产品线，该产品线包含四种可客製化试剂盒。在技​​术进步、医疗保健转型以及现代医学和研究分析需求的推动下，多重检测市场持续发展。

本报告的主要优势：

  • 深入分析：取得以客户群、政府政策和社会经济因素、消费者偏好、垂直产业和其他细分市场为重点的深入市场洞察，涵盖主要地区和新兴地区。
  • 竞争格局：了解主要企业采取的策略倡议，并了解透过正确的策略实现市场渗透的潜力。
  • 市场驱动因素与未来趋势：探索动态因素和关键市场趋势，以及它们将如何塑造未来的市场发展。
  • 可执行的建议：利用洞察力为策略决策提供讯息，从而在动态环境中开拓新的业务管道和收入来源。
  • 受众范围广：对新兴企业、研究机构、顾问公司、中小企业和大型企业都有益处且经济高效。

它是用来做什么的？

产业与市场洞察、商业机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范及其影响、新产品开发、竞争影响

分析范围

  • 历史资料（2021-2025 年）和预测资料（2026-2031 年）
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争对手定位、策略和市场占有率分析
  • 按业务板块和地区（国家）分類的收入成长和预测分析
  • 公司概况（策略、产品、财务资讯、关键趋势等）

目录

第一章执行摘要

第二章市场概述

  • 市场概览
  • 市场定义
  • 分析范围
  • 市场区隔

第三章 商业情境

  • 市场驱动因素
  • 市场限制
  • 市场机会
  • 波特五力分析
  • 产业价值链分析
  • 政策和法规
  • 策略建议

第四章 技术展望

5. 多重检测市场按类型划分

  • 介绍
  • 蛋白质多重检测
  • 核酸多重检测
  • 基于细胞的多重检测

6. 多重检测市场（依产品分类）

  • 介绍
  • 消耗品
  • 装置
  • 软体

7. 多重检测市场（依技术划分）

  • 介绍
  • 流式细胞技术
  • 萤光侦测
  • 发光
  • 多重即时PCR
  • 其他技术

8. 各地区的多重检测市场

  • 介绍
  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 印度
    • 日本
    • 韩国
    • 印尼
    • 泰国
    • 其他的

第九章 竞争格局与分析

  • 主要企业和策略分析
  • 市占率分析
  • 企业合併、协议、商业合作
  • 竞争对手仪錶板

第十章：公司简介

  • Luminex
  • Promega
  • Rndsystems（Biotechne Corporation）
  • Eve Technologies
  • Sigma-Aldrich
  • Bio-Techne
  • Merck Millipore
  • Biocompare
  • Flagship Biosciences

第十一章附录

  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要收益
  • 分析方法
  • 简称
简介目录
Product Code: KSI061615965

The multiplex assay market is forecasted to increase at a 15.45% CAGR, growing from USD 1,607.267 million in 2025 to USD 3806.265 million in 2031.

The multiplex assay market is experiencing significant growth driven by technological advancement, evolving healthcare paradigms, and increasing analytical complexity demands. These sophisticated scientific techniques, enabling simultaneous measurement of multiple analytes or targets within a single sample, have become indispensable tools across biochemistry, molecular biology, medicine, and diagnostics. The convergence of biotechnology sector expansion, personalized medicine adoption, and rising chronic disease prevalence is propelling market momentum.

Core Market Drivers

Intrinsic Technological Advantages

Multiplex assays offer compelling benefits compared to traditional singleplex tests, making them highly valuable across research, diagnostic, and clinical applications. The most significant advantage lies in their ability to analyze multiple analytes-including proteins, nucleic acids, or other molecules-simultaneously within a single sample. This capability provides comprehensive, holistic views of biological processes, disease pathways, and drug responses that would be impossible or impractical to achieve through sequential singleplex testing.

Furthermore, multiplex assays enhance diagnostic accuracy by considering multiple biomarkers or disease indicators concurrently. This multi-parameter approach reduces the likelihood of false positives or negatives, yielding more reliable results and improved patient outcomes. The efficiency gains from analyzing numerous targets simultaneously translate to reduced sample volumes, decreased reagent consumption, faster turnaround times, and lower overall costs per data point-critical considerations in both research and clinical settings.

Pharmaceutical and Biotechnology Expansion

The expanding pharmaceutical sector and advances in molecular diagnostics are substantial market catalysts. Continuous progress in biotechnology, genomics, and proteomics has enabled identification of numerous potential biomarkers and therapeutic targets. Multiplex assays play crucial roles in assessing potential drug effects on multiple targets simultaneously, accelerating drug development timelines and improving research efficiency. The biotechnology landscape is expanding rapidly, with India's biotech startup ecosystem expected to reach 10,000 companies by 2025, demonstrating the sector's global growth trajectory and associated demand for sophisticated analytical tools like multiplex assays.

Personalized Medicine Integration

The healthcare industry's shift toward personalized medicine requires comprehensive understanding of multiple biomarkers, positioning multiplex assays as essential enabling technologies. These assays facilitate simultaneous analysis of diverse genetic, proteomic, and molecular markers, supporting development of tailored treatment strategies optimized for individual patient profiles. The growing adoption of personalized medicine is evidenced by emerging business models-exemplified by the May 2023 launch of Malla, a New York-based startup offering functional and personalized medicine through accessible membership models at $65 monthly, including one-to-one consultations for personalized health planning.

Chronic Disease and Demographic Pressures

Multiplex assays have proven invaluable in studying and managing chronic diseases, offering capabilities to track biomarker changes over time and providing insights into disease dynamics. The rising chronic disease prevalence represents a significant growth driver, with these conditions accounting for 41 million deaths annually-74% of all deaths worldwide. The analytical power of multiplex assays enables comprehensive disease monitoring and management strategies that would be impractical using conventional methods.

Additionally, the growing geriatric population accelerates multiplex assay demand, as elderly individuals commonly present with multiple concurrent conditions including cardiovascular disease and diabetes, requiring complex diagnostic approaches. The demographic shift is substantial: the proportion of people aged over 60 years worldwide is projected to increase from 12% to 22% between 2015 and 2050, creating sustained demand for efficient multi-parameter diagnostic solutions.

Market Constraints

Despite robust growth prospects, the multiplex assay market faces challenges that may impact expansion. Cost represents a significant limiting factor, with initial setup expenses and ongoing costs associated with multiplex assays remaining relatively high. This includes equipment acquisition, reagents, and specialized expertise requirements for assay design and data analysis. These financial barriers may limit adoption, particularly in resource-constrained settings where budget limitations preclude investment in advanced analytical platforms.

Additionally, designing and optimizing multiplex assays involves greater complexity than traditional singleplex approaches. Development requires careful consideration of factors including cross-reactivity, sensitivity, and dynamic range for each analyte, making the process time-consuming and resource-intensive.

Regional Dynamics and Recent Developments

North America is positioned to hold significant market share during the forecast period, supported by higher chronic disease prevalence, growing geriatric populations, increasing R&D spending on drug development, and government support. Approximately one in six people in the U.S. were aged 65 years or above in 2020, accelerating multiplex assay demand.

Recent market developments underscore ongoing innovation. In February 2023, Quansys Biosciences launched a non-human primate model line of multiplex ELISA assays comprising four customizable kits. The multiplex assay market continues evolving, driven by technological sophistication, healthcare transformation, and analytical demands of modern medicine and research.

Key Benefits of this Report:

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, and other sub-segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decisions to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data from 2021 to 2025 & forecast data from 2026 to 2031
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information), and Key Developments among others.

Multiplex Assay Market Segmentation

  • By Type
  • Protein Multiplex Assays
  • Nucleic Acid Multiplex Assays
  • Cell-based Multiples Assays
  • By Product
  • Consumables
  • Instruments
  • Software
  • By Technology
  • Flow Cytometry
  • Fluorescence Detection
  • Luminescence
  • Multiplex Real-time PCR
  • Other Technologies
  • By Geography
  • North America
  • United States
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Thailand
  • Others

TABLE OF CONTENTS

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

  • 2.1. Market Overview
  • 2.2. Market Definition
  • 2.3. Scope of the Study
  • 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Porter's Five Forces Analysis
  • 3.5. Industry Value Chain Analysis
  • 3.6. Policies and Regulations
  • 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. MULTIPLEX ASSAY MARKET BY TYPE

  • 5.1. Introduction
  • 5.2. Protein Multiplex Assays
  • 5.3. Nucleic Acid Multiplex Assays
  • 5.4. Cell-based Multiples Assays

6. MULTIPLEX ASSAY MARKET BY PRODUCT

  • 6.1. Introduction
  • 6.2. Consumables
  • 6.3. Instruments
  • 6.4. Software

7. MULTIPLEX ASSAY MARKET BY TECHNOLOGY

  • 7.1. Introduction
  • 7.2. Flow Cytometry
  • 7.3. Fluorescence Detection
  • 7.4. Luminescence
  • 7.5. Multiplex Real-time PCR
  • 7.6. Other Technologies

8. MULTIPLEX ASSAY MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. India
    • 8.6.3. Japan
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Thailand
    • 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Market Share Analysis
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Luminex
  • 10.2. Promega
  • 10.3. Rndsystems (Biotechne Corporation)
  • 10.4. Eve Technologies
  • 10.5. Sigma-Aldrich
  • 10.6. Bio-Techne
  • 10.7. Merck Millipore
  • 10.8. Biocompare
  • 10.9. Flagship Biosciences

11. APPENDIX

  • 11.1. Currency
  • 11.2. Assumptions
  • 11.3. Base and Forecast Years Timeline
  • 11.4. Key Benefits for the Stakeholders
  • 11.5. Research Methodology
  • 11.6. Abbreviations